Skip to Main Content

An official website of the United States government

Evaluating the Potential for Biomarker Use in CT Screening

Principal Investigator
Name
Hilary Robbins
Degrees
PhD MHS MSPH
Institution
International Agency for Research on Cancer (IARC)
Position Title
Scientist
Email
About this CDAS Project
Study
NLST (Learn more about this study)
Project ID
NLST-476
Initial CDAS Request Approval
Jan 31, 2019
Title
Evaluating the Potential for Biomarker Use in CT Screening
Summary
At IARC, we are part of a large NCI-funded program (U19CA203654) evaluating the potential for genetic and blood-based biomarkers to improve multiple aspects of the lung cancer screening process. Specifically, we aim to assess whether one or more blood-based biomarkers could improve a) selection of ever-smokers into screening or b) management of nodules detected on CT.

We would like to analyze data from the NLST in various ways to help us understand whether use of biomarkers could improve the screening process. These include estimating individual risk during screening, modelling potential cost-effectiveness of incorporating biomarkers, and comparing NLST screening to other CT screening studies.
Aims

1. Develop and validate risk models to calculate individual risk of lung cancer during screening;
2. Evaluate the potential cost-effectiveness of incorporating biomarker testing into the CT screening process;
3. Compare key aspects of the NLST screening process, such as screening benefits and screening harms (including overdiagnosis) to those from other CT screening studies.

Collaborators

Mattias Johansson, IARC
Paul Brennan, IARC
Tricia Larose, IARC
Florence Guida, IARC
Karine Alcala, IARC

Related Publications